Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemia

D. Müller(University of Tübingen), Martin Müller(Carl von Ossietzky Universität Oldenburg), Hans‐Georg Kopp(Robert Bosch Hospital), Jonas S. Heitmann(Universitätsklinikum Tübingen), Marc Sturm(University of Tübingen), Andreas Kirschniak(University of Tübingen), Alexander R. Fuchs(University of Tübingen), Yoshiteru Sasaki(Boston Children's Hospital), Lothar Kanz(University of Freiburg), Michael Haap, Melanie Märklin(University of Tübingen), Stefan Wirths(University of Tübingen)

Journal of Leukocyte Biology

December 17, 2018

10.1002/jlb.2ab0218-076rr

Cited by 12

Related Papers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial

|The Lancet Oncology|2019|1.7k

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

|The Lancet Oncology|2016|738

PI3 Kinase Signals BCR-Dependent Mature B Cell Survival

|Cell|2009|651

Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects

|Current Drug Metabolism|2009|623